Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically
RecruitingNCT07201376
Dartmouth-Hitchcock Medical CenterBenign Skin Growth, Non-Melanoma Skin Cancer (NMSC)
Start: 2025-11-14End: 2027-11-01Target: 125Updated: 2026-02-06